BioSpace News Archive

Medically Home announced a new, $110 million round of funding from strategic investors including Baxter International Inc., Global Medical Response and Cardinal Health who will each have representation on the company’s Board.

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced the unaudited preliminary revenue and year-end cash-position for the financial year 2021.

Alcon announced the closing of its previously announced acquisition of Ivantis®, developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surgery.

Calibre Scientific is pleased to announce the acquisition of Medline Scientific, a distributor of laboratory consumables and equipment with headquarters in Oxfordshire, United Kingdom.

Khondrion announced that the last patient has been dosed with sonlicromanol in the KHENERGYZE Phase IIb clinical study.

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.

Pluristem Therapeutics Inc., a leading biotechnology company, and Tnuva Group, Israel’s largest food producer, announced the launch of an innovative collaboration to develop, manufacture and commercialize cultured cell-based products for the food industry.

Iksuda Therapeutics announced further expansion of its differentiated ADC pipeline through a license and commercialisation agreement with LegoChem Biosciences, a Korean biopharmaceutical company focused on the development of next-generation novel therapeutics utilising its proprietary medicinal drug discovery technologies.

EsoCap announced that the company has entered into a worldwide, exclusive antibody licensing agreement with Upadia, to develop targeted therapeutics to treat Barrett’s esophagus.

Humanigen, Inc. outlined the next steps for the development of its lead candidate, lenzilumab, in the prevention of CAR-T therapy related toxicities including ICANS and CRS in patients with relapsed or refractory Non-Hodgkin lymphoma.